Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies
Objective Abnormal expression of several biomarkers might predict disease prognosis and response to chemotherapy in patients with epithelial ovarian cancer (EOC). However, the published data are inconsistent. Methods Eligible studies that investigated the association between survival or response to...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2013-08, Vol.139 (8), p.1257-1277 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1277 |
|---|---|
| container_issue | 8 |
| container_start_page | 1257 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 139 |
| creator | Xu, Linjuan Cai, Jing Yang, Qiang Ding, Hui Wu, Liying Li, Tao Wang, Zehua |
| description | Objective
Abnormal expression of several biomarkers might predict disease prognosis and response to chemotherapy in patients with epithelial ovarian cancer (EOC). However, the published data are inconsistent.
Methods
Eligible studies that investigated the association between survival or response to platinum-based chemotherapy in EOC and the expression status of Bcl-2, EGFR, GST, LRP, p16, p21, P-gp and TNF-α were identified by an electronic search of PubMed and Embase. The measures of interest were hazard ratio (HR) for survival or risk ratio for chemotherapy response. A meta-analysis was performed using the fixed-effect or random-effect models.
Results
The number of eligible studies analyzed was 27 for Bcl-2, 22 for EGFR, 29 for GST, 12 for LRP, 16 for p16, 22 for p21, 27 for P-gp and three for TNF-α. A meta-analysis showed that high EGFR and P-gp expression was associated with poor overall survival (OS) (pooled adjusted HR = 1.826 and HR = 1.822). Only high GST expression was associated with improved OS (HR = 0.780). Furthermore, high p16 and P-gp expression was associated with poor progression-free survival (PFS) (HR = 1.550 and HR = 2.136). High GST expression was associated with improved PFS (HR = 0.689). Among these factors, only LRP, P-gp and TNF-α were associated with response to platinum-based chemotherapy.
Conclusions
The markers we analyzed are unlikely to be useful as predictors of prognosis and response to platinum-based chemotherapy in EOC patients in clinical practice. |
| doi_str_mv | 10.1007/s00432-013-1435-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1401089284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1401089284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-4fe2b3351f0c9dea59febfabebd85455bb4fd90f56ca73028f675bd9bcb0483e3</originalsourceid><addsrcrecordid>eNp1kU1P3DAQhi3UChbaH8ClslQhcQn15ybpDaF-SUjtAc6W7YwX02ycehIk-PV42S1FSD1Z9jzvjOd9CTnm7IwzVn9CxpQUFeOy4krq6mGPLPjmhUup35AF4zWvtODLA3KIeMvKXddinxwIqVvNRb0g46-cVkPCKXqKcTXEEL0dPNAUKMIdZNtTF9Pa5t-QkcaBwhinG-hjKaQ7m6Md6JMif6aWrmGylR1sf48RNz3G2fURb6CjOM1dBHxH3gbbI7zfnUfk-uuXq4vv1eXPbz8uzi8rr5iYKhVAuLIFD8y3HVjdBnDBOnBdo5XWzqnQtSzopbe1ZKIJy1q7rnXeMdVIkEfkdNt3zOnPDDiZdUQPfW8HSDMarhhnTSsaVdCPr9DbNOeyxBPFZN3yRhaKbymfE2KGYMYciy_3hjOzicNs4zAlDrOJwzwUzYdd59mtoXtW_PW_ACc7wKK3fcjFyYj_uFo3SkheOLHlsJSGFeQXX_zv9EdkyqSr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1400379183</pqid></control><display><type>article</type><title>Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Xu, Linjuan ; Cai, Jing ; Yang, Qiang ; Ding, Hui ; Wu, Liying ; Li, Tao ; Wang, Zehua</creator><creatorcontrib>Xu, Linjuan ; Cai, Jing ; Yang, Qiang ; Ding, Hui ; Wu, Liying ; Li, Tao ; Wang, Zehua</creatorcontrib><description>Objective
Abnormal expression of several biomarkers might predict disease prognosis and response to chemotherapy in patients with epithelial ovarian cancer (EOC). However, the published data are inconsistent.
Methods
Eligible studies that investigated the association between survival or response to platinum-based chemotherapy in EOC and the expression status of Bcl-2, EGFR, GST, LRP, p16, p21, P-gp and TNF-α were identified by an electronic search of PubMed and Embase. The measures of interest were hazard ratio (HR) for survival or risk ratio for chemotherapy response. A meta-analysis was performed using the fixed-effect or random-effect models.
Results
The number of eligible studies analyzed was 27 for Bcl-2, 22 for EGFR, 29 for GST, 12 for LRP, 16 for p16, 22 for p21, 27 for P-gp and three for TNF-α. A meta-analysis showed that high EGFR and P-gp expression was associated with poor overall survival (OS) (pooled adjusted HR = 1.826 and HR = 1.822). Only high GST expression was associated with improved OS (HR = 0.780). Furthermore, high p16 and P-gp expression was associated with poor progression-free survival (PFS) (HR = 1.550 and HR = 2.136). High GST expression was associated with improved PFS (HR = 0.689). Among these factors, only LRP, P-gp and TNF-α were associated with response to platinum-based chemotherapy.
Conclusions
The markers we analyzed are unlikely to be useful as predictors of prognosis and response to platinum-based chemotherapy in EOC patients in clinical practice.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-013-1435-z</identifier><identifier>PMID: 23595127</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Biomarkers ; Biomarkers, Tumor - analysis ; Cancer Research ; Carcinoma, Ovarian Epithelial ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Hematology ; Humans ; Internal Medicine ; Medical sciences ; Medicine ; Medicine & Public Health ; Meta-analysis ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasms, Glandular and Epithelial - drug therapy ; Neoplasms, Glandular and Epithelial - metabolism ; Neoplasms, Glandular and Epithelial - mortality ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - mortality ; Pharmacology. Drug treatments ; Prognosis ; Review ; Studies ; Treatment Outcome ; Tumors</subject><ispartof>Journal of cancer research and clinical oncology, 2013-08, Vol.139 (8), p.1257-1277</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-4fe2b3351f0c9dea59febfabebd85455bb4fd90f56ca73028f675bd9bcb0483e3</citedby><cites>FETCH-LOGICAL-c402t-4fe2b3351f0c9dea59febfabebd85455bb4fd90f56ca73028f675bd9bcb0483e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-013-1435-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-013-1435-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27584231$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23595127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Linjuan</creatorcontrib><creatorcontrib>Cai, Jing</creatorcontrib><creatorcontrib>Yang, Qiang</creatorcontrib><creatorcontrib>Ding, Hui</creatorcontrib><creatorcontrib>Wu, Liying</creatorcontrib><creatorcontrib>Li, Tao</creatorcontrib><creatorcontrib>Wang, Zehua</creatorcontrib><title>Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Objective
Abnormal expression of several biomarkers might predict disease prognosis and response to chemotherapy in patients with epithelial ovarian cancer (EOC). However, the published data are inconsistent.
Methods
Eligible studies that investigated the association between survival or response to platinum-based chemotherapy in EOC and the expression status of Bcl-2, EGFR, GST, LRP, p16, p21, P-gp and TNF-α were identified by an electronic search of PubMed and Embase. The measures of interest were hazard ratio (HR) for survival or risk ratio for chemotherapy response. A meta-analysis was performed using the fixed-effect or random-effect models.
Results
The number of eligible studies analyzed was 27 for Bcl-2, 22 for EGFR, 29 for GST, 12 for LRP, 16 for p16, 22 for p21, 27 for P-gp and three for TNF-α. A meta-analysis showed that high EGFR and P-gp expression was associated with poor overall survival (OS) (pooled adjusted HR = 1.826 and HR = 1.822). Only high GST expression was associated with improved OS (HR = 0.780). Furthermore, high p16 and P-gp expression was associated with poor progression-free survival (PFS) (HR = 1.550 and HR = 2.136). High GST expression was associated with improved PFS (HR = 0.689). Among these factors, only LRP, P-gp and TNF-α were associated with response to platinum-based chemotherapy.
Conclusions
The markers we analyzed are unlikely to be useful as predictors of prognosis and response to platinum-based chemotherapy in EOC patients in clinical practice.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Cancer Research</subject><subject>Carcinoma, Ovarian Epithelial</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasms, Glandular and Epithelial - drug therapy</subject><subject>Neoplasms, Glandular and Epithelial - metabolism</subject><subject>Neoplasms, Glandular and Epithelial - mortality</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Review</subject><subject>Studies</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kU1P3DAQhi3UChbaH8ClslQhcQn15ybpDaF-SUjtAc6W7YwX02ycehIk-PV42S1FSD1Z9jzvjOd9CTnm7IwzVn9CxpQUFeOy4krq6mGPLPjmhUup35AF4zWvtODLA3KIeMvKXddinxwIqVvNRb0g46-cVkPCKXqKcTXEEL0dPNAUKMIdZNtTF9Pa5t-QkcaBwhinG-hjKaQ7m6Md6JMif6aWrmGylR1sf48RNz3G2fURb6CjOM1dBHxH3gbbI7zfnUfk-uuXq4vv1eXPbz8uzi8rr5iYKhVAuLIFD8y3HVjdBnDBOnBdo5XWzqnQtSzopbe1ZKIJy1q7rnXeMdVIkEfkdNt3zOnPDDiZdUQPfW8HSDMarhhnTSsaVdCPr9DbNOeyxBPFZN3yRhaKbymfE2KGYMYciy_3hjOzicNs4zAlDrOJwzwUzYdd59mtoXtW_PW_ACc7wKK3fcjFyYj_uFo3SkheOLHlsJSGFeQXX_zv9EdkyqSr</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Xu, Linjuan</creator><creator>Cai, Jing</creator><creator>Yang, Qiang</creator><creator>Ding, Hui</creator><creator>Wu, Liying</creator><creator>Li, Tao</creator><creator>Wang, Zehua</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130801</creationdate><title>Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies</title><author>Xu, Linjuan ; Cai, Jing ; Yang, Qiang ; Ding, Hui ; Wu, Liying ; Li, Tao ; Wang, Zehua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-4fe2b3351f0c9dea59febfabebd85455bb4fd90f56ca73028f675bd9bcb0483e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Cancer Research</topic><topic>Carcinoma, Ovarian Epithelial</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasms, Glandular and Epithelial - drug therapy</topic><topic>Neoplasms, Glandular and Epithelial - metabolism</topic><topic>Neoplasms, Glandular and Epithelial - mortality</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Review</topic><topic>Studies</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Linjuan</creatorcontrib><creatorcontrib>Cai, Jing</creatorcontrib><creatorcontrib>Yang, Qiang</creatorcontrib><creatorcontrib>Ding, Hui</creatorcontrib><creatorcontrib>Wu, Liying</creatorcontrib><creatorcontrib>Li, Tao</creatorcontrib><creatorcontrib>Wang, Zehua</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Linjuan</au><au>Cai, Jing</au><au>Yang, Qiang</au><au>Ding, Hui</au><au>Wu, Liying</au><au>Li, Tao</au><au>Wang, Zehua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>139</volume><issue>8</issue><spage>1257</spage><epage>1277</epage><pages>1257-1277</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Objective
Abnormal expression of several biomarkers might predict disease prognosis and response to chemotherapy in patients with epithelial ovarian cancer (EOC). However, the published data are inconsistent.
Methods
Eligible studies that investigated the association between survival or response to platinum-based chemotherapy in EOC and the expression status of Bcl-2, EGFR, GST, LRP, p16, p21, P-gp and TNF-α were identified by an electronic search of PubMed and Embase. The measures of interest were hazard ratio (HR) for survival or risk ratio for chemotherapy response. A meta-analysis was performed using the fixed-effect or random-effect models.
Results
The number of eligible studies analyzed was 27 for Bcl-2, 22 for EGFR, 29 for GST, 12 for LRP, 16 for p16, 22 for p21, 27 for P-gp and three for TNF-α. A meta-analysis showed that high EGFR and P-gp expression was associated with poor overall survival (OS) (pooled adjusted HR = 1.826 and HR = 1.822). Only high GST expression was associated with improved OS (HR = 0.780). Furthermore, high p16 and P-gp expression was associated with poor progression-free survival (PFS) (HR = 1.550 and HR = 2.136). High GST expression was associated with improved PFS (HR = 0.689). Among these factors, only LRP, P-gp and TNF-α were associated with response to platinum-based chemotherapy.
Conclusions
The markers we analyzed are unlikely to be useful as predictors of prognosis and response to platinum-based chemotherapy in EOC patients in clinical practice.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>23595127</pmid><doi>10.1007/s00432-013-1435-z</doi><tpages>21</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2013-08, Vol.139 (8), p.1257-1277 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1401089284 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Biomarkers Biomarkers, Tumor - analysis Cancer Research Carcinoma, Ovarian Epithelial Female genital diseases Gynecology. Andrology. Obstetrics Hematology Humans Internal Medicine Medical sciences Medicine Medicine & Public Health Meta-analysis Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasms, Glandular and Epithelial - drug therapy Neoplasms, Glandular and Epithelial - metabolism Neoplasms, Glandular and Epithelial - mortality Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - metabolism Ovarian Neoplasms - mortality Pharmacology. Drug treatments Prognosis Review Studies Treatment Outcome Tumors |
| title | Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A06%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20several%20biomarkers%20in%20epithelial%20ovarian%20cancer:%20a%20meta-analysis%20of%20published%20studies&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Xu,%20Linjuan&rft.date=2013-08-01&rft.volume=139&rft.issue=8&rft.spage=1257&rft.epage=1277&rft.pages=1257-1277&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-013-1435-z&rft_dat=%3Cproquest_cross%3E1401089284%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1400379183&rft_id=info:pmid/23595127&rfr_iscdi=true |